{"id":55963,"date":"2025-07-30T08:47:27","date_gmt":"2025-07-30T08:47:27","guid":{"rendered":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/"},"modified":"2025-07-30T08:47:27","modified_gmt":"2025-07-30T08:47:27","slug":"estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/","title":{"rendered":"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n"},"content":{"rendered":"<p>MAR\u00cdA JES\u00daS PASCUAL CASC\u00d3N &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; MEDPACE SPAIN, S.L.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MAR\u00cdA JES\u00daS PASCUAL CASC\u00d3N &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; MEDPACE SPAIN, S.L.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2901],"tags":[],"class_list":["post-55963","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-be-03"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n - Ibima\" \/>\n<meta property=\"og:description\" content=\"MAR\u00cdA JES\u00daS PASCUAL CASC\u00d3N &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; MEDPACE SPAIN, S.L.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:47:27+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n\",\"datePublished\":\"2025-07-30T08:47:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/\"},\"wordCount\":53,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - BE-03\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/\",\"name\":\"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:47:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n - Ibima","og_description":"MAR\u00cdA JES\u00daS PASCUAL CASC\u00d3N &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; MEDPACE SPAIN, S.L.","og_url":"https:\/\/ibima.eu\/es\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:47:27+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n","datePublished":"2025-07-30T08:47:27+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/"},"wordCount":53,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - BE-03"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/","url":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/","name":"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:47:27+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-multicentrico-en-fase-iii-aleatorizado-con-enmascaramiento-doble-controlado-con-placebo-de-itolizumab-en-combinacion-con-corticoesteroides-para-el-tratamiento-inicial-de-la-enfermedad-agud\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio multic\u00e9ntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinaci\u00f3n con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitri\u00f3n"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=55963"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55963\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=55963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=55963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=55963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}